Enanta Pharmaceuticals, Inc. (ENTA) Stock Analysis

Enanta Pharmaceuticals is a clinical-stage small-molecule drug developer whose current commercial revenue is almost entirely tied to AbbVie’s MAVYRET HCV regimen, incorporating Enanta-discovered glecaprevir. That royalty base is contracting as treated HCV populations shrink, and 54.5% of cash royalties were assigned to OMERS for a $200 million upfront payment in 2023. The strategic pivot is toward wholly owned oral RSV and immunology assets: zelicapavir is moving into the RESOLVE Phase 2b/3 study for high-risk adults, LOTUS is testing pediatric RSV, and EDP-323 offers a second RSV mechanism; EDP-978 and EPS-3903 expand into inflammatory disease. **The key financial constraint is a shrinking, encumbered royalty stream**, although $211.5 million of cash and marketable securities at fiscal Q3 2026 supports operations into FY2029. Q3 revenue of $14.36 million fell 21.6% year over year and missed consensus; the net loss was $19.50 million, or -$0.67 per share. At $11.10, market capitalization was $323.3 million and enterprise value about $111.8 million. Analysts’ 12-month targets of $20.00–$21.83 imply upside, but the valuation hinges on clinical execution. Near-term catalysts include RESOLVE initiation in Q4 2026, an EPS-3903 IND filing in 2H 2026, and 2027 clinical readouts.